Page 7 - Briefing Document News Today

Share this article Share this article NEW YORK, May 5, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") (NASDAQ: CCXI).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether ChemoCentryx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  On May...

Share this article Share this article RADNOR, Pa., May 6, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed against ChemoCentryx, Inc. (NASDAQ: CCXI) ("ChemoCentryx") on behalf of those who purchased or acquired ChemoCentryx common stock between November 26, 2019 and May 3, 2021, inclusive (the "Class Period"). Deadline Reminder: Investors who purchased or acquired ChemoCentryx common stock during the ...

Message : Required fields NEW YORK, May 5, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") (NASDAQ: CCXI).   Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether ChemoCentryx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  On May 4, 2021, ...

Share this article Share this article NEW YORK, May 6, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") (NASDAQ: CCXI) from November 26, 2019 through May 3, 2021 (the "Class Period"). The lawsuit filed in the United States District Court for the Northern District of Califor...

Moderna on Friday evening became the second developer of a COVID-19 vaccine to be granted an emergency use authorization (EUA) by the FDA, allowing patients to be dosed with the company’s messenger RNA (mRNA)-based mRNA-1273—just a week after the agency granted the first. The company said the first doses of mRNA-1273 will be injected into patients next week. Like Pfizer and BioNTech’s BNT162b2, which received an EUA on December 11, mRNA-1273 is a two-dose vaccine. But Moderna’s vaccine...

https://www.hangthecensors.com/483359.html (Natural News) In the development of vaccines against coronaviruses like SARS-COV-1 and MERS in the early 2000’s, researchers found evidence of a serious problem. Teams of U.S. and foreign scientists vaccinated animals with the four most promising vaccines. At first, the experiment seemed successful as all the animals developed a robust antibody response to coronavirus. However, when the scientists exposed the vaccinated animals to the wild virus...

And that is very, very concerning to the american people that that information is being made public. >> leaked from the deep state? so an aide to the president might be part of the deep state, is that what you believe? >> i absolutely believe that it came from someone within that building. there are very few people who are aware of the briefing document that the president was provided and very few people are aware of the conversation that actually took place and there should be accountability. >...

Especially late in the summer. >> if its what you say i love it. >> in other words, if its what you say, research on hillary clinton represented to be from the russian crown prosecutors -- not as donald trump jr. has said in the other statement, that as she has said as theyve said the woman would be in new york not a government official. thats nonsense to suggest he didnt think this was tied to the russian government is absolute nonsense and refuted by the e-mail which donald trump jr. posted as...

Citing reasons why comey should be fired. so i find that -- >> wait. thats in the dags letter? they cite your briefing document from the campaign? >> yes. so as you may recall, back when james comey first did the press conference, which was the incident that they seem to cite as the inappropriate way that he handled this, you had first former attorney general eric holder wrote an op-ed that appeared in "the washington post." >> thats right. i remember that. >> then you had people like mike mukas...

Comfortable defending this. you know, chris, one of the things i find most ironic, i actually remember when that press conference first happened. you know, this is a document that we did during the campaign that cited 100 former members of the department of justice. they pull from this actually for that letter, the initial lette citing reasons why comey should be red. so i find that -- >> wait. thats in the dags letter? they cite your briefing document from the campaign? >> yes. so as you may re...